

Pharmaceutical

industry benchmark

2024



Better with every move.

 **ayvens**
SOCIETE GENERALE GROUP

Contents

Introduction	3
Key insights	5
Most driven car segment	6
Most popular car model	7
Powertrain trends	8
Battery electric vehicle powertrain trends	9
Diesel & petrol vehicle powertrain trends	10
PHEV & hybrid vehicle powertrain trends	11
Average CO₂ emission trends	12
Appendix A: Segmentation – Overview	13





Introduction

In this Pharmaceutical industry benchmark report, the most important fleet trends for Pharmaceutical industry fleets in Europe are highlighted, by comparing the passenger car registrations between 2021 and 2023.

The following definition of the Pharmaceutical industry has been applied:
Companies involved in developing, producing and distributing pharmaceutical products.

This analysis of fleet trends is based on Ayvens' passenger car data from 145 international companies. For the scope and to make sure the data is representative, we've only included countries where at least 100 passenger cars were renewed within the industry each year (2021, 2022 and 2023).

If you would like to know how sustainable this industry compared to other industries please check out our [Sustainable Industry Fleet Ranking 2024](#).

A large, abstract graphic composed of two teal-colored shapes. The left shape is a curved, wedge-like form that tapers towards the bottom left. The right shape is a vertical, trapezoidal form that tapers towards the bottom right. Both shapes are filled with a solid teal color and are set against a dark blue background.

Results 2023

Key insights




The share of diesel cars in pharmaceutical industry fleets is decreasing but, it is decreasing slower than other industries benchmarked causing the pharmaceutical industry to have the worst rating on the share of diesel in fleet in the Fleet Sustainability Ranking by Industry report.



While the share of diesel cars is decreasing more slowly in the pharmaceutical industry, these cars are being primarily replaced by battery electric vehicles (BEVs) and not petrol, hybrids or plug-in hybrids, leading to a “good” rating on the metric for BEVs.



Emissions have decreased across all countries since 2021, largely due to the move away from diesel cars and towards zero emission cars (battery electric vehicles) over low emissions cars (hybrids & PHEVs). Now more than half the countries included in this pharmaceutical industry benchmark have average fleet CO₂ emissions below 100 g/km.



The SUV-D1 segment is the most popular segment in pharmaceutical industry fleets in 2023

Most driven car segments							
	2021		2022		2023		
	Segment	%	Segment	%	Segment	%	
1 st	SUV-C2	15%	SUV-C2	14%	SUV-D1	19%	
2 nd	D2	14%	D2	13%	SUV-C2	15%	
3 rd	SUV-D1	12%	SUV-D1	12%	D2	13%	
4 th	C1	11%	SUV-C1	12%	SUV-D2	11%	
5 th	SUV-D2	10%	SUV-D2	10%	C1	11%	
6 th	D1	9%	C1	9%	SUV-C1	9%	
7 th	SUV-C1	8%	D1	7%	D1	6%	
8 th	C2	6%	C2	6%	C2	5%	
9 th	E2	5%	E2	4%	E2	2%	
10 th	MPV-C	3%	MPV-C	3%	MPV-C	2%	

Most popular segment: SUV-D1

- The SUV-C2 segment was the most popular car segment in 2021 and 2022 but in 2023 dropped down to second position.
- SUVs are overall a popular car model in pharmaceutical industry fleets with over 50% of cars being SUVs.
- Premium car models make up 3 of the 5 most popular cars.

The Volkswagen ID.4 is the most popular car in pharmaceutical industry fleets


	2021 Make & Model	2022 Make & Model	2023 Make & Model
1 st	BMW X1	Peugeot 3008	Volkswagen ID.4
2 nd	BMW 3 Series	BMW X1	Peugeot 3008
3 rd	Volkswagen Passat	BMW 3 Series	Skoda Octavia
4 th	Toyota RAV4	Volkswagen Tiguan	Volkswagen Tiguan
5 th	Toyota Corolla	Volkswagen Passat	BMW X1
6 th	Volkswagen Tiguan	Volkswagen Golf	Tesla Model Y
7 th	Audi Q3	Toyota RAV4	Volkswagen Passat
8 th	Skoda Octavia	Audi Q3	Toyota Corolla
9 th	BMW X3	Skoda Octavia	Toyota RAV4
10 th	Audi A4	Mercedes CLA-Class	Audi Q3

Most popular car:
Volkswagen ID.4




- While the Volkswagen ID.4 is the most popular car in 2023, it is followed closely by the Peugeot 3008, which was the most popular car in 2022.
- Volkswagen is the most popular brand in pharma industry fleets with 3 of the top 10 cars coming from VW.

The share of diesel has decreased since 2021 but at a lower rate than other industries



- Since 2021, the share of plug-in hybrid electric vehicles (PHEVs) and hybrids have slightly decreased in fleet share. While the share of petrol cars has remained fairly stable and increasing by less than a percentage point between 2022 and 2023.
- The decrease in diesel cars has led to the increase in battery electric vehicles (BEVs) with the share of diesel decrease leading to an almost equal increase in BEVs over two years.


All countries have seen a substantial increase in the share of battery electric vehicles in fleet over the past two years




- Austria, Belgium, Bulgaria, Denmark, Germany and Portugal have all seen an almost 20 percentage point increase in the share of BEVs in pharma fleets over the past year.
- While BEV uptake is higher in most western and northern European countries, the share in southern and eastern European countries is at a higher level in pharma industry fleets than fleets in other industries.

Only a few countries have seen large increases in the share of plug-in hybrids and hybrid cars since 2021

PHEV share evolution per country




Hybrid share evolution per country




- The share of plug-in hybrid electric vehicles (PHEVs) has increased the most in Sweden since 2021. Going from less than 20% fleet share in 2021 to 46% in 2023.
- Most countries have kept the share of PHEVs and hybrids in fleet stable over the past 2 years.
- Portugal has decreased the share of hybrid cars in fleet from around 15% in 2021 to 0% in 2023, making the switch the battery electric vehicles.

Most countries have decreased the share of diesel cars in fleet, but at differing levels



- Serbia has the highest share of petrol cars in pharmaceutical industry fleets at 57%, while the country with the 2nd highest level (France) has a share at 38%. France and Serbia are the only two countries that have had large increases in the share of petrol cars in fleet.
- The largest decreases in share of diesel cars in fleet over the past two years have been in Austria, Belgium, Denmark, France and Italy.
- The Netherlands is the only country where the share of diesel cars in pharma industry fleets is at zero in 2023.

More than half of the countries have average CO₂ emissions under 100 g/km in pharma industry fleets


















- Emissions have decreased across all countries since 2021, largely due to the move away from diesel cars and towards zero emission cars (battery electric vehicles) over low emissions cars (hybrids & PHEVs).
- Denmark, UK, Finland and Belgium all have average CO₂ emissions below 50 g/km and Sweden has the lowest average CO₂ emissions in pharma industry fleets at 26 g/km.

*Emissions are based on OEM estimates and not real-world emissions

Appendix A: Segmentation – Overview

The letter indicates the dimensions of the vehicle; C being smaller than E.
 The number indicates the quality level of a brand; 1 being a ‘volume brand’ and 2 being ‘premium brand’

	Volume cars (1)			Premium cars (2)	
	Hatchback / sedan / SW	SUV	MPV	Hatchback / sedan / SW	SUV
Subcompact cars (B)	 B1 – VW Polo	 SUV-B1 – VW T-Cross	Not common	 B2 – Mini Cooper	Not common
Compact cars (C)	 C1 – VW Golf	 SUV-C1 – VW T-Roc	 MPV-C – VW Touran	 C2 – BMW 1 series	 SUV-C2 – BMW X1
Midsized cars (D)	 D1 – VW Passat	 SUV-D1 – VW Tiguan	 MPV-D – VW Sharan	 D2 – BMW 3 series	 SUV-D2 – BMW X3
Full-size cars (E)				 E2 – BMW 5 series	 SUV-E2 – BMW X5

The information in this report is provided on the basis of the sources as listed and information provided by Ayvens. Ayvens makes no representation or warranty (express or implied) of any nature, nor does it accept any responsibility or liability of any kind, with respect to the accurateness, completeness, adequacy or currency of any of the information or opinions contained in this document.

The information contained in this document is derived from sources that have not been independently verified. Ayvens gives no undertaking and is under no obligation to provide the recipient with access to any additional information or to update this document or to correct any inaccuracies in it which may become apparent, and it reserves the right, without giving reasons, at any time and in any respect to amend or withdraw the information described herein.

Your use of information contained in this document is entirely at your own risk. Except in the case of fraudulent misrepresentation, neither Ayvens nor any of its affiliates, advisors or representatives shall have any liability for any direct, indirect, consequential or other losses or damages including loss of profits incurred by you or any third party that may arise from any reliance on (1) this document or for the accurateness, completeness, adequacy or currency thereof or (2) for any other written or oral information made available by Ayvens in connection herewith.



Better with every move.

 **ayvens**
SOCIETE GENERALE GROUP